BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 6601312)

  • 1. Frequencies of HLA and Gm immunogenetic markers in Kaposi's sarcoma.
    Pollack MS; Safai B; Myskowski PL; Gold JW; Pandey J; Dupont B
    Tissue Antigens; 1983 Jan; 21(1):1-8. PubMed ID: 6601312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA studies of endemic African Kaposi's sarcoma patients and matched controls: no association with HLA-DR5.
    Melbye M; Kestens L; Biggar RJ; Schreuder GM; Gigase PL
    Int J Cancer; 1987 Feb; 39(2):182-4. PubMed ID: 3492448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histocompatibility antigens HLA-A, -B, -DR in Greek patients with Kaposi's sarcoma.
    Papasteriades C; Kaloterakis A; Filiotou A; Economidou J; Nicolis G; Trichopoulos D; Stratigos J
    Tissue Antigens; 1984 Nov; 24(5):313-5. PubMed ID: 6335794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of HLA-DR5 with mycosis fungoides.
    Safai B; Myskowski PL; Dupont B; Pollack MS
    J Invest Dermatol; 1983 May; 80(5):395-7. PubMed ID: 6601679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major histocompatibility complex class I to III allotypes in patients with AIDS-related complex/Walter-Reed 5, disseminated Kaposi's sarcoma and in normal controls. The ARC-IVIG Study Group.
    Plum G; Siebel E; Bendick C; Rasokat H; Braun M; Krickeberg H; Mauff G
    Vox Sang; 1990; 59 Suppl 1():15-20. PubMed ID: 2238573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA studies in acquired immune deficiency syndrome patients with Kaposi's sarcoma.
    Prince HE; Schroff RW; Ayoub G; Han S; Gottlieb MS; Fahey JL
    J Clin Immunol; 1984 May; 4(3):242-5. PubMed ID: 6588054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA and Kaposi's sarcoma in Sardinia.
    Contu L; Cerimele D; Pintus A; Cottoni F; La Nasa G
    Tissue Antigens; 1984 Apr; 23(4):240-5. PubMed ID: 6587615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "The sarcoidosis map": a joint survey of clinical and immunogenetic findings in two European countries.
    Martinetti M; Tinelli C; Kolek V; Cuccia M; Salvaneschi L; Pasturenzi L; Semenzato G; Cipriani A; Bartova A; Luisetti M
    Am J Respir Crit Care Med; 1995 Aug; 152(2):557-64. PubMed ID: 7633707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interplay of immunoglobulin G heavy chain markers (Gm) and HLA in predisposing to systemic lupus nephritis.
    Stenszky V; Kozma L; Szegedi G; Farid NR
    J Immunogenet; 1986 Feb; 13(1):11-7. PubMed ID: 3091700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA and Gm genes in systemic lupus erythematosus.
    Whittingham S; Mathews JD; Schanfield MS; Tait BD; Mackay IR
    Tissue Antigens; 1983 Jan; 21(1):50-7. PubMed ID: 6404002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-DR3 and HLA-DR5 associated thyrotoxicosis--two different types of toxic diffuse goiter.
    Schleusener H; Schernthaner G; Mayr WR; Kotulla P; Bogner U; Finke R; Meinhold H; Koppenhagen K; Wenzel KW
    J Clin Endocrinol Metab; 1983 Apr; 56(4):781-5. PubMed ID: 6131902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity by cluster analysis techniques of Graves' patients typed for HLA DR and IgG heavy chain markers.
    Frecker MF; Preus M; Kozma L; Krasrits E; Stenszky V; Balazś C; Farid NR
    Mol Biol Med; 1986 Feb; 3(1):63-71. PubMed ID: 3083192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA in familial and nonfamilial Mediterranean Kaposi's sarcoma in Greece.
    Kaloterakis A; Papasteriades C; Filiotou A; Economidou J; Hadjiyannis S; Stratigos J
    Tissue Antigens; 1995 Feb; 45(2):117-9. PubMed ID: 7792757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kaposi's sarcoma and the HLA-Dr5 alloantigen.
    Ohara N; Chang SW
    Ann Intern Med; 1982 Oct; 97(4):617. PubMed ID: 6982016
    [No Abstract]   [Full Text] [Related]  

  • 15. HLA and Kaposi's sarcoma in solid organ transplantation.
    Brunson ME; Balakrishnan K; Penn I
    Hum Immunol; 1990 Sep; 29(1):56-63. PubMed ID: 2211190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic and immunogenetic features of primary Kaposi's sarcoma.
    Marinig C; Fiorini G; Boneschi V; Melotti E; Brambilla L
    Cancer; 1985 May; 55(9):1899-901. PubMed ID: 3156665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histocompatibility antigens in progressive systemic sclerosis (PSS; scleroderma).
    Lynch CJ; Singh G; Whiteside TL; Rodnan GP; Medsger TA; Rabin BS
    J Clin Immunol; 1982 Oct; 2(4):314-8. PubMed ID: 6982903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA antigen frequencies in HIV-1-related Kaposi's sarcoma.
    Mann DL; Murray C; O'Donnell M; Blattner WA; Goedert JJ
    J Acquir Immune Defic Syndr (1988); 1990; 3 Suppl 1():S51-5. PubMed ID: 2395088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HLA typing in classical and African Kaposi's disease].
    Lemarchand-Venencie F; Lepace V; Belaich S; Civatte J; Rabian C; Chidiac A; Colombani J; Degos L
    Pathol Biol (Paris); 1986 Jun; 34(6):761-4. PubMed ID: 3531992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [T-helper (CD4+) cytopenia and HLA-A1, -B8, -C27, -DR3].
    Kuntz BM; Sobieraj B; Brüster HT
    Beitr Infusionsther Transfusionsmed; 1994; 32():310-3. PubMed ID: 9480115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.